Pharma News

Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa

  • Posted on: 9 June 2017
  • By: PharmaTutor News

Fibrocell Science, Inc. a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, announced that the remaining two patients in the NC1+ cohort have been dosed in the Phase 1 portion of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a devastating genetic skin disease with a high mortality rate. The cohort consists of three patients.


Cell Design Labs announces Issuance of Broad Patent for Chimeric Notch Receptor

  • Posted on: 9 June 2017
  • By: PharmaTutor News

Cell Design Labs, Inc. announced the issuance of U.S. Patent No. 9,670,281, entitled “Binding-triggered transcriptional switches and the methods of use thereof.” This patent, issued to UC San Francisco (UCSF) and exclusively licensed to Cell Design Labs, broadly covers composition of matter for proprietary synNotch™ constructs, cells genetically modified with synNotch receptors and methods for treating diseases.


DCGI relax guidelines for HIV paediatric drugs production

  • Posted on: 9 June 2017
  • By: Shalini.Sharma

The Drug Controller General of India (DCGI) on relaxed guidelines for the production of pediatric HIV drugs, whose supply was affected by regulatory issues. The regulator approved the child-friendly and thermally stable pellet formulation of Lopinavir / Ritonavir without feasibility studies, but said it would control post-marketing surveillance.


AstraZeneca to Present Scientific Advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions

  • Posted on: 8 June 2017
  • By: PharmaTutor News

AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon (exenatide extended-release) for injectable suspension, with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA 9-13 June 2017.


Alkermes announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients

  • Posted on: 8 June 2017
  • By: PharmaTutor News

Alkermes plc announced the initiation of ENLIGHTEN-Early, a supportive study in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia.


Punjab government will set up two Ayush hospitals in the state

  • Posted on: 8 June 2017
  • By: Shalini.Sharma

The government of Punjab will establish two 50-bed Ayush hospitals in the state, Health Minister Brahm Mohindra said. Standardized services of Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homeopathy would also be provided to patients indoors and outdoors in these hospitals, he added.


Govt. of Assam & Tata Trusts sign MoU to provide Comprehensive Cancer Care in the state

  • Posted on: 3 June 2017
  • By: Shalini.Sharma

Government of Assam and Tata Trusts, signed a Memorandum of Understanding to provide comprehensive cancer care and ensure affordable quality treatment for cancer patients in the state. Assam is one of the states that has the highest per capita cancer burden in India. The Memorandum of Understanding was signed under the presence of Shri. Himanta Biswa Sarma, Hon’ble Minister of Health and Family Welfare, Government of Assam along with R. Venkataramanan, Managing Trustee, Tata Trusts.


Pages